Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Low nadir testosterone levels achieved with luteinising hormone-releasing hormone (LHRH) agonist triptorelin correlate with better overall survival and disease-specific survival in advanced prostate cancer patients. This finding supports optimizing testosterone suppression for improved outcomes.
Area Of Science
- Oncology
- Endocrinology
Background
- Advanced prostate cancer treatment often involves androgen deprivation therapy.
- Luteinising hormone-releasing hormone (LHRH) agonists like triptorelin are used to suppress testosterone production.
- The optimal level of testosterone suppression for improved clinical outcomes remains an area of investigation.
Purpose Of The Study
- To evaluate the association between low nadir testosterone levels during triptorelin treatment and clinical outcomes in advanced prostate cancer.
- To determine if achieving specific testosterone suppression targets impacts overall survival (OS) and disease-specific survival (DSS).
Main Methods
- Retrospective analysis of pooled data from three Phase III clinical trials of triptorelin monotherapy.
- Patients were grouped based on nadir testosterone levels: <0.35, <0.7, <1.7, and ≥1.7 nmol/L.
- Overall survival (OS) and disease-specific survival (DSS) were assessed using Kaplan-Meier analysis and log-rank tests.
Main Results
- 96% of patients achieved nadir testosterone <0.35 nmol/L.
- A statistically significant improvement in OS was observed with decreasing nadir testosterone levels (p < 0.001).
- While not significant in primary analysis, sensitivity analyses showed improved DSS with lower nadir testosterone levels (p ≤ 0.03).
Conclusions
- Low nadir testosterone levels achieved with triptorelin are associated with improved OS in advanced prostate cancer.
- Evidence suggests a similar association with improved DSS, particularly in sensitivity analyses.
- These findings highlight the importance of achieving profound testosterone suppression for enhanced patient outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...